Figure 6.
The effectiveness of PRP products was studied for a variety of orthobiological soft tissue pathoanatomic conditions, including tendinopathies, hamstring pathologies, meniscus lesions, and plantar fasciitis. Each of these studies, represented by the circles, has the platelet dose depicted on the X-axis (e.g., in study 24, the platelet dose was on average 3.6 × 109 platelets for all treated patients). Based on the assessment scores between the treatment groups in each study, the Y-axis indicates whether the patient outcomes were positive or negative. It was found that results of studies with identifiers 1–14 were not significantly different when compared with control groups, particularly when platelet doses were less than 1.5 × 109 platelets in the majority of these studies. All markers in blue demonstrated a positive outcome after PRP treatment. A notable characteristic of these studies is that the platelet dose was generally higher than that observed in studies without significant outcomes. Studies involving greater than 3.2 × 109 platelets have generally reported more positive results. (Based on the data provided in each study, the platelet dose was calculated; however, if no platelet count was provided, the baseline count was assumed to be 250.000/µL for all studies. The platelet capture rates and concentration factors were determined using the methods described by Magalon et al. and Fadadu et al. [2,4]).